Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Connecticut Innovation
Deal Size : $10.7 million
Deal Type : Financing
Modifi Bio Raises Additional $4.3 Million in Seed Funding
Details : The financing will be used to further advance Modifi bio's lead molecules towards IND-enabling studies and phase I clinical trials. It works in DNA modification as a novel approach to target cancer.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
October 16, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Connecticut Innovation
Deal Size : $10.7 million
Deal Type : Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : National Cancer Institute
Deal Size : $2.4 million
Deal Type : Funding
Details : The grant will support drug development around a class of molecules targeting cancer cells lacking expression of key DNA repair protein called MGMT (O6-methylguanine methyl transferase), based on a recent publication from the Yale founders’ laboratorie...
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
October 25, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : National Cancer Institute
Deal Size : $2.4 million
Deal Type : Funding
LOOKING FOR A SUPPLIER?
Reset All
